{"pmid":32422569,"title":"Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020.","text":["Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020.","BACKGROUND: To track the European spread of SARS-CoV-2, decentralized testing became necessary and test capacity needed to be expanded outside reference laboratories rapidly. METHODS: We assessed via an online questionnaire the preparedness of European hospital laboratories for detection of SARS-CoV-2 and listed the main drawbacks for implementation. RESULTS: Forty-five percent of the surveyed labs had a test in place by March 26th which is well into the first wave of the pandemic in most countries. CONCLUSIONS: The main implementation barriers for introduction of a SARSCoV-2 molecular assay in European diagnostic laboratories were availability of positive controls and a specificity panel.","J Clin Virol","Matheeussen, Veerle","Loens, Katherine","Lammens, Christine","Vilken, Tuba","Koopmans, Marion","Goossens, Herman","Ieven, Margareta","32422569"],"abstract":["BACKGROUND: To track the European spread of SARS-CoV-2, decentralized testing became necessary and test capacity needed to be expanded outside reference laboratories rapidly. METHODS: We assessed via an online questionnaire the preparedness of European hospital laboratories for detection of SARS-CoV-2 and listed the main drawbacks for implementation. RESULTS: Forty-five percent of the surveyed labs had a test in place by March 26th which is well into the first wave of the pandemic in most countries. CONCLUSIONS: The main implementation barriers for introduction of a SARSCoV-2 molecular assay in European diagnostic laboratories were availability of positive controls and a specificity panel."],"journal":"J Clin Virol","authors":["Matheeussen, Veerle","Loens, Katherine","Lammens, Christine","Vilken, Tuba","Koopmans, Marion","Goossens, Herman","Ieven, Margareta"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422569","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jcv.2020.104432","keywords":["covid","molecular test","pandemic","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1667159284506427392,"score":9.490897,"similar":[{"pmid":32046815,"pmcid":"PMC7029448","title":"Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.","text":["Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020.","Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers.","Euro Surveill","Reusken, Chantal B E M","Broberg, Eeva K","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion","Leitmeyer, Katrin","On Behalf Of Evd-LabNet And Erli-Net","32046815"],"abstract":["Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty-eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers."],"journal":"Euro Surveill","authors":["Reusken, Chantal B E M","Broberg, Eeva K","Haagmans, Bart","Meijer, Adam","Corman, Victor M","Papa, Anna","Charrel, Remi","Drosten, Christian","Koopmans, Marion","Leitmeyer, Katrin","On Behalf Of Evd-LabNet And Erli-Net"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32046815","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.2807/1560-7917.ES.2020.25.6.2000082","keywords":["2019-ncov","coronavirus","emerging infections","laboratory","response","zoonoses"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493011623937,"score":222.57326},{"pmid":32381642,"title":"Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","text":["Understanding, verifying and implementing Emergency Use Authorization molecular diagnostics for the detection of SARS-CoV-2 RNA.","The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens.","J Clin Microbiol","Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B","32381642"],"abstract":["The SARS-CoV-2 pandemic has brought a new wave of challenges to health care, particularly in the area of rapid diagnostic test development and implementation. Acute diagnosis of COVID-19 infection is critically dependent on detection of SARS-CoV-2 RNA from clinical specimens (e.g. nasopharyngeal swabs). While laboratory-developed testing for SARS-CoV-2 is an essential component of diagnostic testing for this virus, the majority of clinical microbiology laboratories are dependent on commercially available SARS-CoV-2 molecular assays. In contrast to assays approved or cleared by the Food and Drug Administration for in vitro diagnostic use, assays for the detection of SARS-CoV-2 nucleic acids have Emergency Use Authorization (EUA) from the FDA. Outside of highly specialized academic and commercial laboratory settings, clinical microbiology laboratories are likely unfamiliar with EUA classification and thus assay verification can be daunting. Further compounding anxiety for laboratories are major issues with supply chain that are dramatically affecting the availability of test reagents and requiring laboratories to implement multiple commercial EUA tests. Here, we describe guidance for the verification of assays with EUA for the detection of SARS-CoV-2 nucleic acid from clinical specimens."],"journal":"J Clin Microbiol","authors":["Mitchell, Stephanie L","St George, Kirsten","Rhoads, Daniel D","Butler-Wu, Susan M","Dharmarha, Vaishali","McNult, Peggy","Miller, Melissa B"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381642","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1128/JCM.00796-20","topics":["Diagnosis"],"weight":1,"_version_":1666419683233890305,"score":176.67184},{"pmid":32435872,"title":"Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","text":["Lab-on-a-Chip Devices for Point-of-Care Medical Diagnostics.","The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays.","Adv Biochem Eng Biotechnol","Arshavsky-Graham, Sofia","Segal, Ester","32435872"],"abstract":["The recent coronavirus (COVID-19) pandemic has underscored the need to move from traditional lab-centralized diagnostics to point-of-care (PoC) settings. Lab-on-a-chip (LoC) platforms facilitate the translation to PoC settings via the miniaturization, portability, integration, and automation of multiple assay functions onto a single chip. For this purpose, paper-based assays and microfluidic platforms are currently being extensively studied, and much focus is being directed towards simplifying their design while simultaneously improving multiplexing and automation capabilities. Signal amplification strategies are being applied to improve the performance of assays with respect to both sensitivity and selectivity, while smartphones are being integrated to expand the analytical power of the technology and promote its accessibility. In this chapter, we review the main technologies in the field of LoC platforms for PoC medical diagnostics and survey recent approaches for improving these assays."],"journal":"Adv Biochem Eng Biotechnol","authors":["Arshavsky-Graham, Sofia","Segal, Ester"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435872","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/10_2020_127","keywords":["centrifugal microfluidics","diagnostics","lab-on-a-chip","microfluidics","paper","point-of-care","smartphone"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393849270272,"score":164.75893},{"pmid":32419713,"pmcid":"PMC7225691","title":"Preparedness and response to Pediatric CoVID-19 in European Emergency Departments: a survey of the REPEM and PERUKI networks.","text":["Preparedness and response to Pediatric CoVID-19 in European Emergency Departments: a survey of the REPEM and PERUKI networks.","Study objective: We aimed to describe the variability and identify gaps in preparedness and response to the COVID-19 pandemic in European EDs caring for children. Methods: A cross-sectional point prevalence survey, was developed and disseminated through the pediatric emergency medicine research networks for Europe (REPEM) and the United Kingdom and Ireland (PERUKI). We aimed to include ten EDs for countries with > 20 million inhabitants and five EDs for less populated countries, unless the number of eligible EDs was below five. ED directors or their delegates completed the survey between March 20(th) and 21(st) to report practice at that time. We used descriptive statistics to analyse data. Results: Overall 102 centers from 18 countries (86% response rate) completed the survey: 34% did not have an ED contingency plan for pandemics and 36% had never had simulations for such events. Wide variation on PPE items was shown for recommended PPE use at pre-triage and for patient assessment, with 62% of centers experiencing shortage in one or more PPE items, most frequently FFP2/N95 masks. Only 17% of EDs had negative pressure isolation rooms. COVID-19 positive ED staff was reported in 25% of centers. Conclusion: We found variation and identified gaps in preparedness and response to the COVID-19 epidemic across European referral EDs for children. A lack in early availability of a documented contingency plan, provision of simulation training, appropriate use of PPE, and appropriate isolation facilities emerged as gaps that should be optimized to improve preparedness and inform responses to future pandemics.","Ann Emerg Med","Bressan, Silvia","Buonsenso, Danilo","Farrugia, Ruth","Parri, Niccolo'","Oostenbrink, Rianne","Titomanlio, Luigi","Roland, Damian","Nijman, Ruud G","Maconochie, Ian","Da Dalt, Liviana","Mintegi, Santiago","32419713"],"abstract":["Study objective: We aimed to describe the variability and identify gaps in preparedness and response to the COVID-19 pandemic in European EDs caring for children. Methods: A cross-sectional point prevalence survey, was developed and disseminated through the pediatric emergency medicine research networks for Europe (REPEM) and the United Kingdom and Ireland (PERUKI). We aimed to include ten EDs for countries with > 20 million inhabitants and five EDs for less populated countries, unless the number of eligible EDs was below five. ED directors or their delegates completed the survey between March 20(th) and 21(st) to report practice at that time. We used descriptive statistics to analyse data. Results: Overall 102 centers from 18 countries (86% response rate) completed the survey: 34% did not have an ED contingency plan for pandemics and 36% had never had simulations for such events. Wide variation on PPE items was shown for recommended PPE use at pre-triage and for patient assessment, with 62% of centers experiencing shortage in one or more PPE items, most frequently FFP2/N95 masks. Only 17% of EDs had negative pressure isolation rooms. COVID-19 positive ED staff was reported in 25% of centers. Conclusion: We found variation and identified gaps in preparedness and response to the COVID-19 epidemic across European referral EDs for children. A lack in early availability of a documented contingency plan, provision of simulation training, appropriate use of PPE, and appropriate isolation facilities emerged as gaps that should be optimized to improve preparedness and inform responses to future pandemics."],"journal":"Ann Emerg Med","authors":["Bressan, Silvia","Buonsenso, Danilo","Farrugia, Ruth","Parri, Niccolo'","Oostenbrink, Rianne","Titomanlio, Luigi","Roland, Damian","Nijman, Ruud G","Maconochie, Ian","Da Dalt, Liviana","Mintegi, Santiago"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419713","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.annemergmed.2020.05.018","locations":["United Kingdom","Ireland"],"countries":["United Kingdom","Ireland"],"countries_codes":["GBR|United Kingdom","IRL|Ireland"],"topics":["Prevention"],"weight":1,"_version_":1667159284560953345,"score":157.81946},{"pmid":32388471,"title":"Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","text":["Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting.","BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting.","J Clin Virol","Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc","32388471"],"abstract":["BACKGROUND: The ongoing SARS-CoV-2 pandemic presents a unique challenge for diagnostic laboratories around the world. Automation of workflows in molecular diagnostics is instrumental for coping with the large number of tests ordered by clinicians, as well as providing fast-tracked rapid testing for highly urgent cases. In this study we evaluated a SARS-CoV-2 LDT for the NeuMoDx 96 system, a fully automated device performing extraction and real-time PCR. METHODS: A publicly available SARS-CoV-2 RT-PCR assay was adapted for the automated system. Analytical performance was evaluated using in-vitro transcribed RNA and clinical performance was compared to the cobas 6800-based reference assay within the lab. RESULTS: The Envelope (E) Gene-LDT displayed good analytical performance with an LoD of 95.55 cp/mL and no false positives during evaluation of cross-reactivity. A total of 176 patient samples were tested with both the E-Gene-LDT and the reference assay. Positive and negative agreement were 100 % and 99.2 % respectively. Invalid-rate was 6.3 %. CONCLUSION: The E-Gene-LDT showed analytical and clinical performance comparable to the cobas6800-based reference assay. Due to its random-access workflow concept and rapid time-to-result of about 80 min, the system is very well suited for providing fast-tracked SARS-CoV-2 diagnostics for urgent clinical samples in the hospital setting."],"journal":"J Clin Virol","authors":["Norz, Dominik","Fischer, Nicole","Schultze, Alexander","Kluge, Stefan","Mayer-Runge, Ulrich","Aepfelbacher, Martin","Pfefferle, Susanne","Lutgehetmann, Marc"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388471","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104390","keywords":["covid-19","neumodx","pcr","rapid testing","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666428892759457792,"score":157.75075}]}